Maybe, but I can't see any reason why he could not have explained that to shareholders.
Ann: SCENESSE European Orphan Drug Designation for VP, page-12
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.53 |
Change
-0.160(1.17%) |
Mkt cap ! $677.3M | |||
| Open | High | Low | Value | Volume |
| $13.70 | $13.87 | $13.52 | $474.9K | 34.75K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 6500 | $13.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.59 | 174 | 1 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |